David Chen‐Li

6.5k total citations · 2 hit papers
23 papers, 4.3k citations indexed

About

David Chen‐Li is a scholar working on Pharmacology, Biological Psychiatry and Clinical Psychology. According to data from OpenAlex, David Chen‐Li has authored 23 papers receiving a total of 4.3k indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Pharmacology, 11 papers in Biological Psychiatry and 8 papers in Clinical Psychology. Recurrent topics in David Chen‐Li's work include Treatment of Major Depression (12 papers), Tryptophan and brain disorders (11 papers) and Chemical synthesis and alkaloids (5 papers). David Chen‐Li is often cited by papers focused on Treatment of Major Depression (12 papers), Tryptophan and brain disorders (11 papers) and Chemical synthesis and alkaloids (5 papers). David Chen‐Li collaborates with scholars based in Canada, Singapore and China. David Chen‐Li's co-authors include Roger S. McIntyre, Hartej Gill, Leanna M.W. Lui, Orly Lipsitz, Flora Nasri, Roger Ho, Amna Majeed, Lee Phan, Jiaqi Xiong and Michelle Iacobucci and has published in prestigious journals such as SHILAP Revista de lepidopterología, Journal of Affective Disorders and Psychiatry Research.

In The Last Decade

David Chen‐Li

23 papers receiving 4.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Impact of COVID-19 pandemic on mental health in the general population: A systematic review

2020 3.5k citations Jiaqi Xiong, Orly Lipsitz et al. Journal of Affective Disorders profile →
Government response moderates the mental health impact of COVID-19: A systematic review and meta-analysis of depression outcomes across countries

2021 157 citations Yena Lee, Leanna M.W. Lui et al. Journal of Affective Disorders profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
David Chen‐Li Canada	14	3.0k	918	678	638	495	23	4.3k
Lee Phan Canada	15	2.8k 0.9×	908 1.0×	656 1.0×	694 1.1×	516 1.0×	46	4.2k
Michelle Iacobucci Canada	17	2.8k 0.9×	924 1.0×	662 1.0×	740 1.2×	523 1.1×	26	4.4k
Amna Majeed Canada	15	3.0k 1.0×	1.0k 1.1×	795 1.2×	671 1.1×	535 1.1×	26	4.9k
Orly Lipsitz Canada	20	3.1k 1.0×	928 1.0×	684 1.0×	733 1.1×	497 1.0×	51	4.8k
Jiaqi Xiong China	8	2.8k 0.9×	876 1.0×	652 1.0×	570 0.9×	481 1.0×	13	3.9k
Flora Nasri Canada	22	3.3k 1.1×	1.1k 1.2×	817 1.2×	798 1.3×	577 1.2×	47	5.2k
João Maurício Castaldelli-Maia Brazil	28	2.3k 0.8×	1.1k 1.2×	951 1.4×	472 0.7×	452 0.9×	210	5.1k
Stefano Ferracuti Italy	34	3.5k 1.2×	1.0k 1.1×	573 0.8×	694 1.1×	365 0.7×	265	6.2k
Antonio Ventriglio Italy	31	2.9k 1.0×	1.4k 1.5×	1.1k 1.7×	528 0.8×	362 0.7×	302	5.7k
Ravi Philip Rajkumar India	22	2.5k 0.8×	790 0.9×	564 0.8×	412 0.6×	325 0.7×	155	4.1k

Countries citing papers authored by David Chen‐Li

Since Specialization

Citations

This map shows the geographic impact of David Chen‐Li's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Chen‐Li with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Chen‐Li more than expected).

Fields of papers citing papers by David Chen‐Li

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David Chen‐Li. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Chen‐Li. The network helps show where David Chen‐Li may publish in the future.

Co-authorship network of co-authors of David Chen‐Li

This figure shows the co-authorship network connecting the top 25 collaborators of David Chen‐Li. A scholar is included among the top collaborators of David Chen‐Li based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David Chen‐Li. David Chen‐Li is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Chen‐Li, David, et al.. (2025). Non-hallucinogenic psychedelics for mood and anxiety disorders: A systematic review. Psychiatry Research. 349. 116532–116532. 1 indexed citations

Chen‐Li, David, et al.. (2024). Protocols and practices in psilocybin assisted psychotherapy for depression: A systematic review. Journal of Psychiatric Research. 176. 77–84. 11 indexed citations

Rodrigues, Nelson B., et al.. (2024). Brain-derived neurotrophic factor Val66Met and CYP2B6 polymorphisms as predictors for ketamine effectiveness in patients with treatment-resistant depression. Journal of Psychopharmacology. 38(4). 375–381. 6 indexed citations

Choi, Charles Q., et al.. (2024). Mechanisms of psilocybin on the treatment of posttraumatic stress disorder. Journal of Psychopharmacology. 4116335731–4116335731. 2 indexed citations

Chen‐Li, David, et al.. (2024). Effect of intravenous ketamine on suicidality in adults with treatment-resistant depression: A real world effectiveness study. Psychiatry Research. 343. 116282–116282. 1 indexed citations

Gill, Hartej, David Chen‐Li, Roger S. McIntyre, et al.. (2024). Adjunctive cariprazine for major depressive disorder: a systematic review and meta-analysis. CNS Spectrums. 29(4). 233–242. 3 indexed citations

Meshkat, Shakila, Joshua D. Di Vincenzo, David Chen‐Li, et al.. (2023). Oral ketamine for depression: An updated systematic review. The World Journal of Biological Psychiatry. 24(7). 545–557. 36 indexed citations

Chen‐Li, David, et al.. (2023). Psilocybin-assisted therapy for depression: A systematic review and meta-analysis. Psychiatry Research. 329. 115531–115531. 45 indexed citations

Alnefeesi, Yazen, David Chen‐Li, Muhammad Youshay Jawad, et al.. (2022). Real-world effectiveness of ketamine in treatment-resistant depression: A systematic review & meta-analysis. Journal of Psychiatric Research. 151. 693–709. 109 indexed citations

10.

Jawad, Muhammad Youshay, Yazen Alnefeesi, Felicia Ceban, et al.. (2022). Lumateperone for the Treatment of Adults With Schizophrenia: a Systematic Review. Current Psychiatry Reports. 24(8). 359–368. 10 indexed citations

11.

Chen‐Li, David, Leanna M.W. Lui, Joshua D. Rosenblat, et al.. (2022). Ketamine as Potential Treatment for Postpartum Depression: A Narrative Review. Annals of Clinical Psychiatry. 34(4). 264–274. 13 indexed citations

12.

Jawad, Muhammad Youshay, Yazen Alnefeesi, Leanna M.W. Lui, et al.. (2022). Olanzapine and samidorphan combination treatment: A systematic review. Journal of Affective Disorders. 301. 99–106. 16 indexed citations

13.

McIntyre, Roger S., Joshua D. Rosenblat, Nelson B. Rodrigues, et al.. (2021). The effect of intravenous ketamine on cognitive functions in adults with treatment-resistant major depressive or bipolar disorders: Results from the Canadian rapid treatment center of excellence (CRTCE). Psychiatry Research. 302. 113993–113993. 22 indexed citations

14.

Lee, Yena, Leanna M.W. Lui, David Chen‐Li, et al.. (2021). Government response moderates the mental health impact of COVID-19: A systematic review and meta-analysis of depression outcomes across countries. Journal of Affective Disorders. 290. 364–377. 157 indexed citations breakdown →

15.

Lui, Leanna M.W., Yena Lee, Orly Lipsitz, et al.. (2021). The influence of prescriber and patient gender on the prescription of benzodiazepines: results from the Florida Medicaid Dataset. CNS Spectrums. 27(3). 378–382. 4 indexed citations

16.

Xiong, Jiaqi, Orly Lipsitz, David Chen‐Li, et al.. (2020). The acute antisuicidal effects of single-dose intravenous ketamine and intranasal esketamine in individuals with major depression and bipolar disorders: A systematic review and meta-analysis. Journal of Psychiatric Research. 134. 57–68. 86 indexed citations

17.

McIntyre, Roger S., Lee Phan, Leanna M.W. Lui, et al.. (2020). Registered clinical trials investigating ketamine for psychiatric disorders. Journal of Psychiatric Research. 127. 1–12. 23 indexed citations

18.

Xiong, Jiaqi, Orly Lipsitz, Flora Nasri, et al.. (2020). Impact of COVID-19 pandemic on mental health in the general population: A systematic review. Journal of Affective Disorders. 277. 55–64. 3542 indexed citations breakdown →

19.

Lee, Yena, Bing Xiang Yang, Dan Luo, et al.. (2020). Synergistic effect of social media use and psychological distress on depression in China during the COVID‐19 epidemic. Psychiatry and Clinical Neurosciences. 74(10). 552–554. 21 indexed citations

20.

Gill, Hartej, Barjot Gill, David Chen‐Li, et al.. (2020). The emerging role of psilocybin and MDMA in the treatment of mental illness. Expert Review of Neurotherapeutics. 20(12). 1263–1273. 32 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact